NUS Links:
The drug Selinexor blocks specific protein that has been shown to be overexpressed in many types of cancer. Authors in this study evaluated the tolerability and the safety of this drug in Asian patients with advanced cancer and metastatic malignancies. Findings identified the recommended dose that can be used for future Selinexor monotherapy and drug combination studies for Asian patients.
Read more: https://journals.sagepub.com/doi/full/10.1177/17588359221087555
This research, led by N2CR members Prof Goh Boon Cher and Prof Shazib Pervaiz with Dr Jayshree Hirpara as the …
Detecting cancer-driving mutations is crucial for understanding cancer and developing treatments. Existing prediction tools vary in accuracy. N2CR member A/Prof …
Led by N2CR member A/Prof Polly Chen, this research highlights the crucial role of ‘death associated protein 3’ (DAP3) in …